ClinicalTrials.gg
CompletedNCT01458951OCTAVEUpdated Jun 1, 2016Results posted

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of tofacitinib and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 182 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-01.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
547
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.

Enrollment
4th of 14
547 · median 107
Started
2012
with 3 others
Phase 3
5 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
7 of 14
Pfizer

Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing tofacitinib in Colitis, Ulcerative, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Tofacitinib
  • CP-690
  • 550
  • Moderate to severe ulcerative colitis
  • phase 3 clinical trial
  • Mayo score
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 18 years of age.
  • Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.
  • Subjects with moderately to severely active UC based on Mayo score criteria.
  • Subjects must have failed or be intolerant of at least one of the following treatments for UC:

    • (oral or intravenous).
    • Azathioprine or 6 mercaptopurine (6 MP).
    • Anti TNF therapy.

Exclusion criteria

Exclusion Criteria:

  • Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.
  • Subjects with disease limited to distal 15 cm.
  • Subjects without previous treatment for UC (ie, treatment naïve).
  • Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
547 participants (actual)

Study arms

  • Experimental
    tofacitinib 10 mg BID

    Drug: tofacitinib

  • Placebo comparator
    Placebo BID

    Drug: Placebo

Interventions

  • 10 mg oral BID

    Also known as: CP-690,550

  • DrugPlacebo

    Placebo oral BID

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Remission at Week 8

    Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of Ulcerative Colitis . It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Achieving Mucosal Healing at Week 8

    Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Week 8

  2. Percentage of Participants Achieving Clinical Response at Week 8

    Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding sub score of at least 1 point or an absolute rectal bleeding sub score of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Week 8

  3. Percentage of Participants With Endoscopic Remission at Week 8

    Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Week 8

  4. Percentage of Participants With Clinical Remission at Week 8

    Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Week 8

  5. Percentage of Participants With Symptomatic Remission at Week 8

    Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Week 8

  6. Percentage of Participants With Deep Remission at Week 8

    Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Week 8

  7. Partial Mayo Scores

    A partial mayo score (mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) and each grading from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline, Weeks 2, 4, 8

  8. Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8

    Change in Partial Mayo scores at Weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each graded from 0 to 3 with higher scores indicating more severe disease.

    Time frame: Baseline, Weeks 2, 4, 8

  9. Change From Baseline in Total Mayo Score at Week 8

    Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

    Time frame: Baseline, Week 8

07

Results

Posted Jun 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
Started4296112
Completed397597
Not completed32115
Withdrew: Other100
Withdrew: Protocol violation510
Withdrew: Withdrawal by subject202
Withdrew: Adverse event702
Withdrew: Insufficient clinical response17011

Outcome measures

PrimaryPercentage of Participants With Remission at Week 8

Remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. Mayo score is an instrument designed to measure disease activity of Ulcerative Colitis . It consisted of 4 subscores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician global assessment (PGA), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Remission at Week 816.63.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.0005 · Percentage difference: 13.0 · 95% CI 8.1 to 17.9
SecondaryPercentage of Participants Achieving Mucosal Healing at Week 8

Mucosal healing in participants was defined by Mayo endoscopic subscore of 0 or 1. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Mucosal Healing at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving Mucosal Healing at Week 828.411.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.0002 · Percentage difference: 16.8 · 95% CI 9.5 to 24.1
SecondaryPercentage of Participants Achieving Clinical Response at Week 8

Clinical response in participants was defined by a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the rectal bleeding sub score of at least 1 point or an absolute rectal bleeding sub score of 0 or 1. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving Clinical Response at Week 855.028.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = <0.0001 · Percentage difference: 26.4 · 95% CI 16.8 to 36.0
SecondaryPercentage of Participants With Endoscopic Remission at Week 8

Endoscopic remission in participants was defined by Mayo endoscopic subscore of 0. The Mayo endoscopic subscore consisted of the findings of centrally read flexible proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Endoscopic Remission at Week 87.01.8
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.0425 · Percentage difference: 5.2 · 95% CI 1.8 to 8.6
SecondaryPercentage of Participants With Clinical Remission at Week 8

Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Clinical Remission at Week 816.83.6
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.0004 · Difference in percentage: 13.2 · 95% CI 8.3 to 18.1
SecondaryPercentage of Participants With Symptomatic Remission at Week 8

Symptomatic remission was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and 0 subscore for both rectal bleeding and stool frequency. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Symptomatic Remission at Week 810.72.7
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.0090 · Percentage difference: 8.0 · 95% CI 3.9 to 12.2
SecondaryPercentage of Participants With Deep Remission at Week 8

Deep remission in participants was defined by a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and 0 subscore for both rectal bleeding and endoscopic subscores. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Deep Remission at Week 8
percentage of participantsTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants With Deep Remission at Week 85.11.8
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · CMH Chi-square Test · p = 0.1408 · Percentage difference: 3.3 · 95% CI 0.1 to 6.6
SecondaryPartial Mayo Scores

A partial mayo score (mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) and each grading from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline, Weeks 2, 4, 8
Reported as:
Mean · units on a scale
Partial Mayo Scores
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Baseline (n= 428, 112 )6.4 ± 1.36.4 ± 1.2
Week 2 (n= 419, 107 )4.4 ± 2.25.4 ± 1.7
Week 4 (n= 412, 102 )3.7 ± 2.34.8 ± 2.0
Week 8 (n= 401, 98 )3.3 ± 2.34.5 ± 2.1
SecondaryChange From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8

Change in Partial Mayo scores at Weeks 2, 4, 8 relative to baseline were reported. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each graded from 0 to 3 with higher scores indicating more severe disease.

Time frame:
Baseline, Weeks 2, 4, 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Change at Week 2 (n= 418, 107 )-2.0 ± 0.1-1.0 ± 0.2
Change at Week 4 (n= 411, 102 )-2.7 ± 0.1-1.5 ± 0.2
Change at Week 8 (n= 400, 98 )-3.0 ± 0.1-1.7 ± 0.2
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -1.0 · 95% CI -1.4 to -0.6
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -1.2 · 95% CI -1.6 to -0.7
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -1.3 · 95% CI -1.7 to -0.9
SecondaryChange From Baseline in Total Mayo Score at Week 8

Change in total Mayo scores at Week 8 relative to Baseline was reported. Mayo score is an instrument designed to measure disease activity of UC. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible centrally read proctosigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher score indicating more severe disease.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in Total Mayo Score at Week 8
units on a scaleTofacitinib 10 mg BIDPlacebo BID
Baseline (n=428,112)9.0 ± 1.58.9 ± 1.5
Change at Week 8 (n=396,98)-3.7 ± 2.8-2.0 ± 2.4
Statistical analysis
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = <0.0001 · Least square mean difference: -1.6 · 95% CI -2.2 to -1.0

Adverse events

Collected over Baseline up to Day 98. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 10 mg BID—18/429 (4.2%)68/429 (15.9%)
Tofacitinib 15 mg BID—0/6 (0%)4/6 (66.7%)
Placebo BID—9/112 (8%)20/112 (17.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
Colitis ulcerativeGastrointestinal disorders8/4290/64/112
AnaemiaBlood and lymphatic system disorders0/4290/61/112
Anal fistulaGastrointestinal disorders0/4290/61/112
Intestinal perforationGastrointestinal disorders0/4290/61/112
DehydrationMetabolism and nutrition disorders0/4290/61/112
Colon neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4290/61/112
Abdominal painGastrointestinal disorders2/4290/60/112
Cardiac failure congestiveCardiac disorders1/4290/60/112
ConstipationGastrointestinal disorders1/4290/60/112
Crohn's diseaseGastrointestinal disorders1/4290/60/112
Most frequent other events
Most frequent other events
EventTofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BID
AnaemiaBlood and lymphatic system disorders11/4291/62/112
Abdominal pain upperGastrointestinal disorders7/4291/60/112
Vulvovaginal candidiasisInfections and infestations0/4291/60/112
ContusionInjury, poisoning and procedural complications1/4291/60/112
Urine analysis abnormalInvestigations0/4291/60/112
HypercholesterolaemiaMetabolism and nutrition disorders7/4291/60/112
HypertriglyceridaemiaMetabolism and nutrition disorders0/4291/60/112
HeadacheNervous system disorders33/4290/69/112
Abdominal painGastrointestinal disorders7/4290/66/112
ArthralgiaMusculoskeletal and connective tissue disorders11/4290/66/112

Baseline characteristics

The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.

Age, Customized
Age, Customized(participants)Tofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BIDTotal
18 to 44 Years265572342
45 to 64 Years139135175
Greater Than or Equal to (>=) 65 Years250530
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 10 mg BIDTofacitinib 15 mg BIDPlacebo BIDTotal
Female170357230
Male259355317
08

Study locations

182 sites
  • Desert Sun Clinical Research, LLC
    Tucson, Arizona 85710, United States
  • Desert Sun Gastroenterology
    Tucson, Arizona 85710, United States
  • Desert Sun Surgery Center
    Tucson, Arizona 85710, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Clinical Application Laboratories
    San Diego, California 92103, United States
  • San Diego Endoscopy Center
    San Diego, California 92103, United States
  • UCSF Endoscopy Unit at Mount Zion
    San Francisco, California 94115, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Bristol Hospital
    Bristol, Connecticut 06010, United States
  • Connecticut Clinical Research Foundation
    Bristol, Connecticut 06010, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Central Connecticut Endoscopy Center
    Plainville, Connecticut 06062, United States
  • Citrus Surgery & Endoscopy Center (Colonoscopy)
    Crystal River, Florida 34429, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Suncoast Endoscopy Center (colonoscopy)
    Inverness, Florida 34453, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Advanced Gastroenterology Center
    Port Orange, Florida 32127, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Endoscopy Center
    Port Orange, Florida 32127, United States
  • Port Orange Urgent Care
    Port Orange, Florida 32127, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Gastrointestinal Specialists, A.M.C.
    Shreveport, Louisiana 71103, United States
  • Shreveport Endoscopy Center, A.M.C.
    Shreveport, Louisiana 71103, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Chevy Chase Endoscopy Center (Endoscopies Only)
    Chevy Chase, Maryland 20815, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Surgery Center of Columbia
    Columbia, Missouri 65201, United States
  • Hannibal Regional Hospital
    Hannibal, Missouri 63401, United States
  • Audrain Medical Center
    Mexico, Missouri 65265, United States
  • Center for Digestive & Liver Disease, Inc.
    Mexico, Missouri 65265, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • South Jersey Gastroenterology
    Marlton, New Jersey 08053, United States
  • The Gastroenterology Group of South Jersey
    Vineland, New Jersey 08360, United States
  • The Endo Center at Voorhees
    Voorhees, New Jersey 08043, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Carolina Research - Carolina Digestive Diseases
    Greenville, North Carolina 27834, United States
  • Regional Gastroenterology Associates of Lancaster, Ltd.
    Lancaster, Pennsylvania 17604, United States
  • Vanderbilt University Medical Center - IBD Clinic
    Nashville, Tennessee 37212-1375, United States
  • Vanderbilt University Medical Center - GI Research Office
    Nashville, Tennessee 37212-1610, United States
  • Vanderbilt University Medical Center - Drug Shipment
    Nashville, Tennessee 37232-7610, United States
  • Vanderbilt University Medical Center - GCRC
    Nashville, Tennessee 37232, United States
  • Vanderbilt University Medical Center - Heart Station
    Nashville, Tennessee 37232, United States
  • Vanderbilt University Medical Center - Radiology
    Nashville, Tennessee 37232, United States
  • Texas Clinical Research Institiute
    Arlington, Texas 76012, United States
  • Austin Gastroenterology PA/Professional Quality Research, Inc.
    Austin, Texas 78705, United States
  • Austin Gastroenterology PA
    Austin, Texas 78745, United States
  • Austin Endoscopy Center II
    Austin, Texas 78746, United States
  • Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • VCU Health System Digestive Health Center
    Richmond, Virginia 23298, United States
  • VCU Health System Endoscopy Suite
    Richmond, Virginia 23298, United States
  • VCU Medical Center Investigational Drug Service (IDS)
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University, Clinical Research Services (CRSU)
    Richmond, Virginia 23298, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Concord Hospital -Concord Repatriation Hospital
    Concord, New South Wales 2139, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital Eastern Campus
    Liverpool, New South Wales 2170, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
  • Krankenhaus Barmherzige Brueder St. Veit/Glan
    St. Veit an der Glan, 9300, Austria
  • GZA St Vincentius
    Antwerpen, 2018, Belgium
  • AZ Groeninge, Campus Kennedylaan
    Kortrijk, 8500, Belgium
  • H-Hartziekenhuis Roeselare-Menen vzw
    Roeselare, 8800, Belgium
  • Hospital de Clinicas de Porto Alegre - HCPA
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre
    Edmonton, Alberta T6G 2B7, Canada
  • University of Alberta - Zeidler Ledcor Centre
    Edmonton, Alberta T6G 2X8, Canada
  • Montreal General Hospital - McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • Saskatoon City Hospital
    Saskatoon, Saskatchewan S7K 0M7, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Instituto de Coloproctologia ICO S.A.S.
    Medellin, Antioquia 00000, Colombia
  • University Hospital Center Osijek, Clinic of Internal Medicine,
    Osijek, 31000, Croatia
  • University Hospital Center Rijeka
    Rijeka, 51000, Croatia
  • University Hospital Center Zagreb,Department of Gastroenterology
    Zagreb, 10000, Croatia
  • Nemocnice Strakonice, a.s., Interni oddeleni
    Strakonice, 386 29, Czech Republic
  • Krajska Zdravotni a.s., Masarykova nemocnice Usti nad Labem, o.z.
    Usti nad Labem, 40113, Czech Republic
  • Bispebjerg Hospital
    Copenhagen, NV 2400, Denmark
  • Hvidovre University Hospital
    Hvidovre, 2650, Denmark
  • Odense University Hospital
    Odense C, 5000, Denmark
  • ECG Unit, Innomedica OU and Qualitas AS (ECG Only)
    Tallinn, 10117, Estonia
  • Innomedica OU
    Tallinn, 10117, Estonia
  • X-Ray Unit, Qualitas AS (X-Ray Only)
    Tallinn, 10117, Estonia
  • East Tallinn Central Hospital Internal Medicine Clinic
    Tallinn, 10138, Estonia
  • ECG Unit, East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • X-Ray Unit, East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • Quattromed HTI Laboratorid OU
    Tallinn, 12618, Estonia
  • Mammograaf OU (Endoscopy Only)
    Tallinn, 13419, Estonia
  • CHU Amiens PICARDIE - Hopital SUD
    Amiens Cedex 1, 80054, France
  • Hopital Saint Andre
    Bordeaux cedex, 33075, France
  • Hopital Beaujon
    Clichy Cedex, 92110, France
  • Hopital Saint Antoine
    Paris Cedex 12, 75571, France
  • C.H.U. de Reims - Hôpital Robert Debré
    Reims cedex, 51092, France

Showing the first 100 of 182 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084. PubMed 36342120 ↗
  • Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program. Patient. 2023 Mar;16(2):95-103. doi: 10.1007/s40271-022-00603-w. Epub 2022 Nov 7. PubMed 36336750 ↗
  • Winthrop KL, Vermeire S, Long MD, Panes J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96. doi: 10.1093/ibd/izac063. PubMed 35648151 ↗
  • Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 Jul;112(1):90-100. doi: 10.1002/cpt.2601. Epub 2022 Apr 27. PubMed 35380740 ↗
  • Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023 Jan 5;29(1):51-61. doi: 10.1093/ibd/izac061. PubMed 35380664 ↗
  • Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1442-1453. doi: 10.1111/apt.16626. Epub 2021 Oct 6. PubMed 34614208 ↗
  • Farraye FA, Qazi T, Kotze PG, Moore GT, Mundayat R, Lawendy N, Sharma PP, Judd DT. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021 Aug;54(4):429-440. doi: 10.1111/apt.16439. Epub 2021 Jun 24. PubMed 34165201 ↗
  • Rubin DT, Reinisch W, Greuter T, Kotze PG, Pinheiro M, Mundayat R, Maller E, Fellmann M, Lawendy N, Modesto I, Vavricka SR, Lichtenstein GR. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Therap Adv Gastroenterol. 2021 May 16;14:17562848211005708. doi: 10.1177/17562848211005708. eCollection 2021. PubMed 34035832 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 Mar;20(3):591-601.e8. doi: 10.1016/j.cgh.2021.02.043. Epub 2021 Mar 6. PubMed 33684552 ↗
  • Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 Mar;10(3):229-240. doi: 10.1002/cpdd.899. Epub 2021 Jan 29. PubMed 33513294 ↗
  • Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408. doi: 10.1093/ibd/izaa289. PubMed 33324993 ↗
  • Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3. doi: 10.1016/j.cgh.2020.10.038. Epub 2020 Oct 27. PubMed 33127596 ↗
  • Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227. PubMed 32870265 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panes J. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. Inflamm Bowel Dis. 2021 Jun 15;27(7):983-993. doi: 10.1093/ibd/izaa193. PubMed 32794567 ↗
  • Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panes J. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2021 May 17;27(6):816-825. doi: 10.1093/ibd/izaa199. PubMed 32766762 ↗
  • Sandborn WJ, Panes J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. doi: 10.1111/apt.15514. Epub 2019 Oct 9. PubMed 31599001 ↗
  • Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3. doi: 10.1016/j.cgh.2019.04.059. Epub 2019 May 8. PubMed 31077827 ↗
  • Sandborn WJ, Panes J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23. PubMed 30476584 ↗
  • Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10. PubMed 30012431 ↗
  • Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131. PubMed 29850873 ↗
  • Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018 Apr;16(2):233-245. doi: 10.5217/ir.2018.16.2.233. Epub 2018 Apr 30. Erratum In: Intest Res. 2018 Jul;16(3):499-501. doi: 10.5217/ir.2018.16.3.499. PubMed 29743836 ↗
  • Panes J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133. Erratum In: J Crohns Colitis. 2019 Jan 1;13(1):139-140. doi: 10.1093/ecco-jcc/jjy135. PubMed 29028981 ↗
  • Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panes J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. PubMed 28467869 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2011
First posted
Oct 25, 2011
Start
Jun 2012
Primary completionActual
May 2015
CompletionActual
Jun 2015
Results first posted
Jun 1, 2016
Last update
Jun 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01458951
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 25, 2011
Start date
Jun 2012
Primary completion
May 2015
Completion
Jun 2015
Results posted
Jun 1, 2016
Last update
Jun 1, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion